Humacyte, Inc. (NASDAQ:HUMA) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Humacyte, Inc. (NASDAQ:HUMA) have earned an average recommendation of “Moderate Buy” from the eight brokerages that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $6.4286.

A number of equities analysts recently commented on the company. Wall Street Zen upgraded Humacyte from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. BTIG Research dropped their price objective on Humacyte from $3.00 to $2.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Weiss Ratings restated a “sell (e+)” rating on shares of Humacyte in a report on Friday, April 10th. Benchmark increased their price objective on Humacyte to $2.00 and gave the stock a “speculative buy” rating in a report on Monday. Finally, HC Wainwright restated a “buy” rating and issued a $3.00 price objective on shares of Humacyte in a report on Tuesday, May 26th.

Insider Buying and Selling

In other news, Director Kathleen Sebelius acquired 56,818 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The shares were purchased at an average price of $0.88 per share, for a total transaction of $49,999.84. Following the completion of the acquisition, the director owned 148,025 shares of the company’s stock, valued at approximately $130,262. This represents a 62.30% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Dale A. Sander sold 45,887 shares of the stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $0.90, for a total value of $41,298.30. Following the completion of the transaction, the chief financial officer owned 267,213 shares in the company, valued at $240,491.70. This represents a 14.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 3.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Humacyte

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC grew its holdings in Humacyte by 50.3% during the fourth quarter. SG Americas Securities LLC now owns 34,075 shares of the company’s stock valued at $33,000 after purchasing an additional 11,411 shares during the last quarter. Independent Advisor Alliance grew its holdings in Humacyte by 49.4% during the third quarter. Independent Advisor Alliance now owns 36,240 shares of the company’s stock valued at $63,000 after purchasing an additional 11,991 shares during the last quarter. Prudential Financial Inc. acquired a new position in Humacyte during the second quarter valued at approximately $28,000. Price T Rowe Associates Inc. MD grew its holdings in Humacyte by 21.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 76,017 shares of the company’s stock valued at $73,000 after purchasing an additional 13,175 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in Humacyte by 41.2% during the second quarter. The Manufacturers Life Insurance Company now owns 45,960 shares of the company’s stock valued at $96,000 after purchasing an additional 13,407 shares during the last quarter. Institutional investors and hedge funds own 44.71% of the company’s stock.

Humacyte Price Performance

Shares of HUMA opened at $1.45 on Thursday. The company has a market capitalization of $321.93 million, a price-to-earnings ratio of -2.54 and a beta of 2.45. Humacyte has a fifty-two week low of $0.55 and a fifty-two week high of $2.93. The company has a debt-to-equity ratio of 5.46, a current ratio of 3.93 and a quick ratio of 3.32. The business’s 50-day moving average is $0.84 and its 200-day moving average is $1.03.

Humacyte (NASDAQ:HUMA) last issued its earnings results on Wednesday, May 13th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. The company had revenue of $0.50 million for the quarter, compared to the consensus estimate of $1.46 million. Humacyte had a negative return on equity of 2,914.18% and a negative net margin of 4,836.06%. Equities research analysts expect that Humacyte will post -0.32 EPS for the current fiscal year.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.